CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,132 enrolled
Drug / intervention
CO2 standard therapy +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03084081
NCT03084081N/ACompleted

A Randomized Controlled Trial Comparing Cure Rates of Cervical Intraepithelial Neoplasia Grade 2 and Higher (CIN2+) Treated With CO2-based Cryotherapy, CropPen, and Thermoablation (UH3)

The Cleveland Clinic·interventional·Posted Mar 20, 2017·Updated Apr 6, 2025

In Brief

A clinical study evaluating CO2 standard therapy, CryoPen, and 1 other intervention for Cervical Intraepithelial Neoplasia. Completed, enrolled 1,132 participants across 3 sites in 3 countries.

Detailed Summary

The purpose of this academic-industrial partnership will compare the CryoPen® and thermoablator to traditional CO2-based cryotherapy for the treatment of cervical precancer in low and middle income countries (LMICs) and investigate whether the cure rates of cervical intraepithelial neoplasia 2 and more severe diagnoses (CIN2+) with these devices are non-inferior compared to that of conventional cryotherapy. The results of this study will affect other research areas by serving as a springboard to exploring treatment alternatives that are amenable to low-resource settings and thus will reach the most vulnerable populations.

Study Details

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMar 20, 2017
Enrollment StartAug 1, 2017
Primary CompletionAug 15, 2024
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 9.3 years ago

Interventions

CO2 standard therapydevice

Standard therapy using carbon dioxide for freezing of tissue

CryoPendevice

Provides a means of freezing tissue without the use of gases or liquids

Thermocoagulatordevice

Thermoablation